muscle as a surrogate for health status in human heart failure. Exerc. Sport Sci. Rev., Vol. 44, No. 1, pp. 45Y50, 2016. We propose the hypothesis that soleus muscle function may provide a surrogate measure of functional capacity in patients with heart failure. We summarize literature pertaining to skeletal muscle as a locus of fatigue and present our recent findings, using in vivo imaging in combination with biomechanical experimentation and modeling, to reveal novel structure-function relationships in chronic heart failure skeletal muscle and gait. Key Words: active force, passive force, strength, skeletal muscle, heart failure, exercise training
A BRIEF HISTORY OF EXERCISE AND SKELETAL MUSCLE FUNCTION IN CHRONIC HEART FAILURE MANAGEMENT
The 11th edition of Harrison's Textbook of Internal Medicine, published in 1987, stated that treatment of heart failure should ''consist of reducing physical activity, instituting rest, and reducing afterload.'' By the early 2000s, the American Heart Association concluded that exercise training in chronic heart failure (CHF) was ''safe and beneficial overall in improving peak V O 2peak , peak workload, exercise duration, and parameters of submaximal exercise performance. In addition, quality of life improvesI.'' (27) . This statement led other peak bodies to produce recommendations such as: ''When medically stable, all CHF patients should be considered for referral to an exercise program'' (22) .
The narrative underlying this paradigm shift is an exemplar of translational research in exercise science, with ultimate global impact on patient management. The story has several starting points, including recognition of the importance of peak oxygen uptake (V O 2peak ) as an index of systemic and integrated physiological function that outperforms traditional indices used in prognostication and transplant stratification (19) , identification of skeletal muscle as an important locus of exercise intolerance in heart failure (8) , courageous early exercise training studies illustrating the reversibility of such limitations (31) , ambitious studies indicating that training could induce improvement in outcomes (2) , and establishment of the hemodynamic safety of well-controlled and targeted exercise interventions (3) . There also are early examples of patient-centered individualization of exercise prescription using novel and targeted approaches (15, 17) , a trend that is only now emerging as a mainstream agenda.
In this brief article, we revisit and acknowledge the important contributions made by studies that indicated peripheral limitations to performance are amenable to modification in CHF. We also present some recent findings using contemporary techniques for the study of skeletal muscle function in vivo to pose the novel hypothesis that soleus (SOL) muscle function may provide a valid surrogate measure for functional capacity and health status in patients with CHF. every year V for an estimated total of 22 million affected. In the United States, recent data indicate that 5.1 million people are affected by CHF and it is one of the most common reasons for hospital admission and general practitioner consultations in the elderly. Despite some improvement across recent decades, the mortality rates associated with CHF remain very high, with a reported risk-adjusted 1-year mortality of 29.6% in 2008 in the United States (4) .
CLINICAL RELEVANCE OF THE LOCUS OF THE SYMPTOMS OF FATIGUE IN CHRONIC HEART FAILURE
Poor exercise tolerance is a cardinal symptom of CHF, which significantly impacts quality of life and the capacity to perform tasks of daily living (6, 9) . Peak oxygen uptake outperforms ejection fraction and hemodynamic indices in terms of prognostication (19) and is used to guide transplantation and ventricular assist device implantation (19, 20) .
Research during the past two decades has identified an intriguing paradox in CHF, in that the primary locus of exercise intolerance often lies in the skeletal muscle, rather than the heart itself (7, 26) . Aerobic capacity and resting cardiac function are poorly correlated in patients with CHF (9). Instead, peripheral factors including impaired blood flow (17) and skeletal muscle dysfunction (6) have a greater bearing on aerobic capacity and are linked intrinsically to the exercise intolerance in this condition.
Recognition of the importance of peripheral abnormalities in CHF led to the ''skeletal muscle hypothesis'' (6) , which proposes that activation of muscle ergoreceptors (receptors activated during muscle contractions that mediate physiologic adjustments) generates symptoms during exercise and that muscle wasting contributes to a wicked cycle of reflex neurohormonal activation, peripheral vasoconstriction, disease progression, and physical inactivity ( Fig. 1 ). Consistent with the muscle hypothesis, muscle wasting is correlated strongly with reduced aerobic capacity (5) and poor prognosis (1) . A recent analysis of 200 CHF patients revealed that reduced muscle mass is associated independently with lower absolute V O 2peak (in milliliters per minute) when age, sex, ejection fraction, and comorbidities were accounted for, and that muscle mass is linked directly to disease progression (11) . These findings place skeletal muscle function at center stage when exercise-based strategies are devised to target functional limitation in a large proportion of patients with stable CHF.
SKELETAL MUSCLE ARCHITECTURE AND MECHANICS IN HUMAN CHRONIC HEART FAILURE
Muscle architecture is linked closely to in vivo muscle mechanics. Muscle volume is one of the primary determinants of the muscle's capacity to generate mechanical work. Maximal muscle force and thus also joint torque production, on the other hand, are associated more closely with muscle physiological cross-sectional area (PCSA) (29) . PCSA is determined Figure 1 . Model depicting the impact of peripheral limitations in chronic heart failure (CHF) based on (6) . Abnormalities in skeletal muscle limit exercise capacity and exacerbate symptoms. Personalized exercise prescription is proposed as a means to reverse the progression of the disease by acting on three different pathways influencing skeletal muscle health, namely, the muscles' morphological and architectural properties, their mechanical properties, and their functional characteristics during movement.
by muscle volume, as well as fiber length and pennation angle (25) . Although some studies have examined muscle size in the context of strength and functional limitations in CHF (12), few have investigated detailed architectural parameters.
In addition, two mechanical properties that influence in vivo muscle mechanics independently of muscle volume and PCSA are its fiber operating lengths and velocities (forcelength and force-velocity properties). To the best of our knowledge, no previous studies have examined fiber length and velocity characteristics of skeletal muscle in CHF. It is accepted widely that muscles operating outside their optimal length and velocity ranges are restricted severely in their ability to produce force, work, and power, resulting in loss of function (29) . The capacity of muscle to generate mechanical work is optimal when it functions over the plateau region of the force-length curve. When skeletal muscle operates outside this range (e.g., if muscle fiber lengths are reduced), mechanical work and power production are compromised drastically. Although abnormalities in CHF skeletal muscle structure such as atrophy and a shift to type II fibers (6) and decreased cross-bridge kinetics (21) make them susceptible to suboptimal function, muscle architecture and mechanics as a limitation to skeletal muscle function have not been studied previously in CHF.
RECENT STUDIES RELATING PLANTARFLEXOR MUSCLE MORPHOLOGY AND FUNCTION TO EXERCISE CAPACITY IN CHRONIC HEART FAILURE
We recently reported alterations on the functional and morphological properties of the plantarflexor muscles in patients affected by CHF (New York Heart Association (NYHA) Class IIYIV; ejection fraction, G40% T 10%; age, 62 T 10 yr; mean T SD) (25) , relative to control participants matched for age, sex, adiposity, and physical activity levels.
These studies are based on detailed measurements of muscle architecture using state-of-the-art three-dimensional ultrasound imaging (dynamic B-mode imaging coupled with simultaneous motion capture of the probe) and estimates of active and passive muscle loads from a novel framework incorporating empirical data (dynamic muscle fascicle imaging, electromyography, and dynamometry) and musculoskeletal modeling. In an effort to maximize accuracy, the derived estimates of muscle loads took into account agonist and antagonist muscle actions, muscle-tendon dynamics, and subjectspecific muscle moment arm data (Fig. 2) .
Despite a similar overall lower limb lean mass, CHF patients exhibited approximately 25% lower combined triceps surae volume ( Fig. 3A) and PCSA (25) . These reductions in triceps surae size were explained primarily by the marked reductions in the SOL. A strong correlation (r = 0.93) was observed between absolute triceps surae volume and V O 2peak in CHF patients but not control participants. Furthermore, body massYspecific SOL volume, unlike the other triceps surae muscles, correlated strongly with body mass-specific V O 2peak in CHF (Fig. 3B) . The SOL is a key locomotor and postural muscle in humans, and these data, together with a strong correlation between body mass-normalized plantarflexor strength and mass-specific V O 2peak in CHF patients (25) , raise the possibility that the SOL may be a sentinel skeletal muscle in terms of identifying the severity of functional impairment in CHF.
These findings were corroborated (23) by observation that the smaller SOL of CHF patients generated lower absolute voluntary active and passive forces (at equivalent levels of passive strain) compared with healthy individuals (Fig. 4) . Importantly, however, this difference was not present when the data were normalized by muscle cross-sectional area or volume ( Fig. 4 ) nor were the normalized active or passive force-length curves different (normalized to optimal fascicle lengths). This detailed single-muscle analysis suggested to us that the reduced muscle force in CHF may be associated more strongly with muscle size than muscle structural, mechanical, or bioenergetic properties.
Similar findings were observed for the SOL muscle when subjects performed isokinetic contractions over the functional ankle range of motion, suggesting a reduction of the total amount of mechanical work generated by the muscle fibers in CHF (Fig. 5A ). Nevertheless, isokinetic experiments revealed that the ability of the SOL muscle to produce mechanical work is not compromised in CHF when the data were normalized by muscle volume (Fig. 5B ).
Notwithstanding the aforementioned findings, which tend to implicate SOL muscle size rather than intrinsic muscle function as a limitation in CHF, we observed some evidence of altered muscle properties in CHF patients. The CHF group exhibited approximately 20% (P G 0.05) shorter optimal fascicle lengths (i.e., the length where peak voluntary isometric force was achieved) as well as shorter passive fascicle lengths compared with those of the age-matched control group (23) . The shorter passive fascicle lengths resulted in a higher passive force for a given absolute muscle length. It is possible that shorter fascicle lengths result in the muscle operating at longer lengths compared with that of healthy individuals during functional tasks such as walking. This could, in turn, result in altered force-length-velocity characteristics of the muscle that lead to a reduced force and work capacity. Conversely, a shorter optimal fascicle length in CHF might accommodate a more compliant Achilles tendon in CHF, which in turn may result from a smaller tendon cross-sectional area (25) . Although the precise mechanisms underlying these characteristics have not been defined, they probably reflect a complex interplay between neurohumoral activation, impaired peripheral blood flow, and reduced activity levels. For example, impaired peripheral blood flow in CHF may have a more pronounced effect on distal compared with proximal limb muscles, whereas the greater reduction in SOL muscle volume compared with the medial gastrocnemius may reflect the relative contribution to mechanical work among the lower limb muscles during walking (25) . This is an intriguing area that requires further detailed experimentation.
The morphological and functional abnormalities we report earlier in this article, particularly in the plantarflexors, could provide a harbinger of impaired function and fatigue (i.e., initial reduction in the contractile capabilities of the muscle with consequent clinical symptoms of fatigue) early in the clinical course in CHF. In another recent study (24) , we compared the mechanics of walking in CHF with that of a healthy matched population. Minimal differences in preferred speed or overall joint kinematics and kinetics were observed between groups, findings that may be explained by optimization of the mechanical cost of transport (i.e., the amount of mechanical work performed per distance traveled; in Joules per kilogram per meter). Nevertheless, when normalized to triceps surae volume, a twofold increase in ankle plantarflexion work was required in CHF. This, together with a greater reliance on the ankle to power walking in CHF patients, may contribute to the mechanisms underlying reduced exercise capacity and marked fatigability in CHF.
An important caveat related to the studies described above is that they were undertaken in patients with heart failure associated with impaired ejection fraction. Further studies are required to establish whether a similar relationship exists between aerobic capacity and SOL function in patients with heart failure and preserved ejection fraction. 
IMPLICATIONS FOR DESIGN OF EXERCISE INTERVENTIONS
Studies of exercise training have established that the skeletal muscle limitations to function are amenable to improvement (7, 14, 15, 17) and that exercise training improves functional capacity, cardiovascular mortality (32), hospitalizations (10) , and quality of life (35) . These benefits typically occur in the absence of changes in cardiac function (2, 26) . The HF-Action trial, which randomized 2331 heart failure subjects (NYHA IIYIV; ejection fraction, G35%), indicated that, after adjustment for prognostic factors, exercise training was associated with a 15% decrease in cardiovascular mortality/CHF hospitalizations. It was concluded that ''The HF-ACTION study supports a structured exercise training program for patients with reduced LV function and HF symptoms in addition to evidence-based therapy'' (32) . However, few attempts have been made to address the question of which exercise prescription will optimize outcomes in HF. Commentary relating to the HF-ACTION trial included ''The one thing this trial does not show is what type of exercise to advocate'' (32) .
Logically, interventions that present the muscle with an intense stimulus while minimizing cardiovascular burden have the potential to amplify functional gains while minimizing acute exercise risk. In accordance with this theoretical framework, we developed in the 1990s individually tailored circuit weight training programs focusing on isolated muscle groups and based on comprehensive a priori exercise testing (15, 17) . Because the exercises were performed on isolated muscle groups at any one time, the intensity of effort was relatively high, whereas the cardiovascular burden was modest (3, 13) . We also successfully established the physiological benefits of such programs in other clinical conditions in a series of experiments (16, 33, 34) . These studies were among the first to use resistance modalities in CHF and they directly informed the development of new exercise strategies that are now recognized internationally (27) . This work also has translated directly into changes in the management of CHF in Australia and elsewhere (30) .
Despite advances in knowledge and clinical practice that have resulted from the development of individually tailored exercise interventions aimed at reversing physiological limitations in CHF, no previous study has specifically devised exercise training programs based on ameliorating deficits in muscle mechanics (e.g., muscle architecture including muscle length and mechanical force and work capacities). This is surprising, given the accepted importance in CHF of abnormalities in length-tension relationships of cardiac myocytes (i.e., Frank-Starling impacts) and also because of the proven benefits of training interventions focused on improving muscle mechanics in subjects with other forms of skeletal myopathies (28) . The questions that now emerge include ''How can exercise training interventions that specifically target limitations in muscle mechanics be designed for large cohorts of patients in a manner that is time efficient, tolerable, and effective?'' This is a future challenge for researchers in the domain of clinical cardiovascular exercise science.
IMPLICATIONS FOR CLINICAL SURVEILLANCE
Cardiorespiratory fitness (VO 2peak testing) is assessed routinely in patients with CHF because of its strong prognostic value (18) . Such tests are expensive and require a high degree of operator expertise and training. The close relationship observed between SOL muscle function and aerobic capacity in patients with CHF makes a case for the serial assessment of SOL muscle function for monitoring changes in clinical status across time. Although the studies cited in this article have used isokinetic dynamometry, protocols to assess SOL muscle strength and endurance that use resistance exercise equipment routinely available in cardiac rehabilitation programs could quite easily be developed. Similarly, we have developed noninvasive ultrasound-based approaches to the quantification of the volume of the triceps surae (25) , which are cheap and suitable for use in patients with implanted devices, who are contraindicated for magnetic resonance imaging. Such assessments would logically be conducted by exercise specialists, with results conveyed to medical staff to support clinical surveillance. The degree to which changes in SOL and other skeleletal muscle size and function relate to, or predict, changes in clinical status should form the basis of future research to test and refine such protocols.
SUMMARY
Skeletal muscle function is an important locus of the clinical symptoms of fatigue in heart failure, with implications related to survival, stratification for transplant, and ventricular assist device implantation. To optimize exercise training for subjects with CHF, the limitations to performance must first be fully understood. Taken together, our recent studies of the skeletal muscle mechanics of patients with CHF suggest abnormalities in the triceps surae. In particular, the SOL appears to be particularly susceptible to muscle wasting and impaired aerobic capacity that characterize CHF. They also highlight a link between the morphological and functional alterations of the calf muscles and fatigue experienced during walking in CHF. Our recent integrated muscle-level and functional gait analyses indicate that reversing these limitations may depend foremost on restoring muscle size, although muscle functional characteristics (in particular, muscle length) may play a further important role. Abnormalities in SOL muscle volume and function may provide a sentinel for detection of early decompensation and a target for specifically designed interventional strategies, although further work is required to develop three-dimensional ultrasound approaches. It is conceivable that, in time, assessment of triceps surae volume and function will become more feasible and cheaper with less user dependence. We hope that this brief article raises useful hypotheses for future studies aimed at individualized detection of disease progression and the earliest and most effective rehabilitative intervention.
